Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies

Abbott, 2002, Drug resistance in epilepsy: the role of the blood-brain barrier, 38 Alberici, 1969, Glutamic acid decarboxylase inhibition and ultrastructural changes by the convulsant drug allylglycine, Biochem. Pharmacol., 18, 137, 10.1016/0006-2952(69)90018-5 Arrowsmith, 2013, Trial watch: phase II and phase III attrition rates 2011–2012, Nat. Rev. Drug Discov., 12, 569, 10.1038/nrd4090 Arrowsmith, 2011, Trial watch: phase III and submission failures: 2007–2010, Nat. Rev. Drug Discov., 10, 87, 10.1038/nrd3375 Auvin, 2012, Novel animal models of pediatric epilepsy, Neurotherapeutics, 9, 245, 10.1007/s13311-012-0119-8 Bankstahl, 2011, A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier, J. Neurosci., 31, 8803, 10.1523/JNEUROSCI.6616-10.2011 Bankstahl, 2012, Generation and characterization of pilocarpine-sensitive C57BL/6 mice as a model of temporal lobe epilepsy, Behav. Brain Res., 230, 182, 10.1016/j.bbr.2012.02.004 Bankstahl, 2013, Pilocarpine-induced epilepsy in mice alters seizure thresholds and the efficacy of antiepileptic drugs in the 6-Hertz psychomotor seizure model, Epilepsy Res., 107, 205, 10.1016/j.eplepsyres.2013.09.014 Bankstahl, 2014, Prolonged depth electrode implantation in the limbic system increases the severity of status epilepticus in rats, Epilepsy Res., 108, 802, 10.1016/j.eplepsyres.2014.01.025 Bar-Klein, 2014, Losartan prevents acquired epilepsy via TGF-beta signaling suppression, Ann. Neurol., 75, 864, 10.1002/ana.24147 Baraban, 2014, What new modeling approaches will help us identify promising drug treatments?, Adv. Exp. Med. Biol., 813, 283, 10.1007/978-94-017-8914-1_23 Baraban, 2013, Drug screening and transcriptomic analysis in Scn1a zebrafish mutants identifies potential lead compound for Dravet Syndrome, Nat. Commun., 4, 2410, 10.1038/ncomms3410 Barba, 2007, Correlation between provoked ictal SPECT and depth recordings in adult drug-resistant epilepsy patients, Epilepsia, 48, 278, 10.1111/j.1528-1167.2007.00935.x Barba, 2012, Diagnostic yield and predictive value of provoked ictal SPECT in drug-resistant epilepsies, J. Neurol., 259, 1613, 10.1007/s00415-011-6387-0 Barker-Haliski, 2014, What are the arguments for and against rational therapy for epilepsy?, Adv. Exp. Med. Biol., 813, 295, 10.1007/978-94-017-8914-1_24 Barton, 2001, Pharmacological characterization of the 6Hz psychomotor seizure model of partial epilepsy, Epilepsy Res., 47, 217, 10.1016/S0920-1211(01)00302-3 Bauer, 2014, Cortical excitability as a potential clinical marker of epilepsy: a review of the clinical application of transcranial magnetic stimulation, Int. J. Neural Syst., 24, 1430001, 10.1142/S0129065714300010 Beery, 2011, Sex bias in neuroscience and biomedical research, Neurosci. Biobehav. Rev., 35, 565, 10.1016/j.neubiorev.2010.07.002 Benatar, 2007, Lost in translation: treatment trials in the SOD1 mouse and in human ALS, Neurobiol. Dis., 26, 1, 10.1016/j.nbd.2006.12.015 Bender, 2007, Epileptogenesis in the developing brain: what can we learn from animal models?, Epilepsia, 48, 2, 10.1111/j.1528-1167.2007.01281.x Berg, 2003, How long does it take for partial epilepsy to become intractable?, Neurology, 60, 186, 10.1212/01.WNL.0000031792.89992.EC Bethmann, 2007, Resistance to phenobarbital extends to phenytoin in a rat model of temporal lobe epilepsy, Epilepsia, 48, 816, 10.1111/j.1528-1167.2007.00980.x Bethmann, 2008, Antiepileptic drug resistant rats differ from drug responsive rats in GABAA-receptor subunit expression in a model of temporal lobe epilepsy, Neurobiol. Dis., 31, 169, 10.1016/j.nbd.2008.01.005 Bialer, 2010, Key factors in the discovery and development of new antiepileptic drugs, Nat. Rev. Drug Discov., 9, 68, 10.1038/nrd2997 Bialer, 2009, Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX), Epilepsy Res., 83, 1, 10.1016/j.eplepsyres.2008.09.005 Bialer, 2015, Progress report on new antiepileptic drugs: a summary of the Twelfth Eilat Conference (EILAT XII), Epilepsy Res., 111, 85, 10.1016/j.eplepsyres.2015.01.001 Blackwood, 1982, Enhanced rate of kindling after prolonged electrode implantation into the amygdala of rats, J. Neurosci. Meth., 5, 343, 10.1016/0165-0270(82)90004-8 Blanco, 2009, Assessment of seizure susceptibility in pilocarpine epileptic and nonepileptic Wistar rats and of seizure reinduction with pentylenetetrazole and electroshock models, Epilepsia, 50, 824, 10.1111/j.1528-1167.2008.01797.x Blumenfeld, 2008, Early treatment suppresses the development of spike-wave epilepsy in a rat model, Epilepsia, 49, 400, 10.1111/j.1528-1167.2007.01458.x Bröer, 2015, Novel combinations of phenotypic biomarkers predict development of epilepsy in the lithium-pilocarpine model of temporal lobe epilepsy in rats, Epilepsy Behav., 53, 98, 10.1016/j.yebeh.2015.09.028 Brandt, 2014, Antiepileptic efficacy of lamotrigine in phenobarbital-resistant and -responsive epileptic rats: a pilot study, Epilepsy Res., 108, 1145, 10.1016/j.eplepsyres.2014.05.008 Brandt, 2003, Epileptogenesis and neuropathology after different types of status epilepticus induced by prolonged electrical stimulation of the basolateral amygdala in rats, Epilepsy Res., 55, 83, 10.1016/S0920-1211(03)00114-1 Brandt, 2004, Striking differences in individual anticonvulsant response to phenobarbital in rats with spontaneous seizures after status epilepticus, Epilepsia, 45, 1488, 10.1111/j.0013-9580.2004.16904.x Brandt, 2006, The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy, Neurobiol. Dis., 24, 202, 10.1016/j.nbd.2006.06.014 Brandt, 2015, Effective termination of status epilepticus by rational polypharmacy in the lithium-pilocarpine model in rats: window of opportunity to prevent epilepsy and prediction of epilepsy by biomarkers, Neurobiol. Dis., 75, 78, 10.1016/j.nbd.2014.12.015 Brodie, 1969, Is man a unique animal in response to drugs?, Am. J. Pharm. Sci. Support. Public Health, 141, 21 Brodie, 2011, Combining antiepileptic drugs–rational polytherapy?, Seizure, 20, 369, 10.1016/j.seizure.2011.01.004 Brooks-Kayal, 2013, Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy, Epilepsia, 54, 44, 10.1111/epi.12298 Broomall, 2014, Pediatric super-refractory status epilepticus treated with allopregnanolone, Ann. Neurol., 76, 911, 10.1002/ana.24295 Brown, 1953, Comparative assay of antiepileptic drugs by pychomotor seizure test and minimal electroshock threshold test, J. Pharmacol. Exp. Ther., 107, 273 Calcagni, 2002, Ictal brain SPET during seizures pharmacologically provoked with pentylenetetrazol: a new diagnostic procedure in drug-resistant epileptic patients, Eur. J. Nucl. Med. Mol. Imaging, 29, 1298, 10.1007/s00259-002-0879-1 Carvey, 1998, The delivery of drugs to the CNS: Systemic delivery with central action, 34 Chen, 1951, The anticonvulsant activity of o-phenyl succinimides, J. Pharmacol. Exp. Ther., 103, 54 Clayton, 2014, Policy: NIH to balance sex in cell and animal studies, Nature, 509, 282, 10.1038/509282a Cornford, 1986, Epilepsy and the blood-brain barrier, Adv. Neurol., 44, 787 Czuczwar, 2009, Pharmacodynamic interactions between antiepileptic drugs: preclinical data based on isobolography, Expert Opin. Drug Metab. Toxicol., 5, 131, 10.1517/17425250802677826 D’Ambrosio, 2010, What is an epileptic seizure? Unifying definitions in clinical practice and animal research to develop novel treatments, Epilepsy Curr., 10, 61, 10.1111/j.1535-7511.2010.01358.x D’Ambrosio, 2005, Progression from frontal-parietal to mesial-temporal epilepsy after fluid percussion injury in the rat, Brain, 128, 174, 10.1093/brain/awh337 D’Ambrosio, 2009, Functional definition of seizure provides new insight into post-traumatic epileptogenesis, Brain, 132, 2805, 10.1093/brain/awp217 D’Ambrosio, 2013, Mild passive focal cooling prevents epileptic seizures after head injury in rats, Ann. Neurol., 73, 199, 10.1002/ana.23764 D’Ambrosio R., Eastman C.L., Miller J.W., 2015. Inadequate experimental methods and erroneous epilepsy diagnostic criteria result in confounding acquired focal epilepsy with genetic absence epilepsy. arXiv:1509 01206 [q-bio NC]. Dalby, 1997, Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin, Epilepsy Res., 28, 63, 10.1016/S0920-1211(97)00031-4 Deckers, 2000, Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed, Epilepsia, 41, 1364, 10.1111/j.1528-1157.2000.tb00111.x Denayer, 2014, Animal models in translational medicine: validation and prediction, New Hor. Transl. Med., 2, 5 Depaulis, 2006, Genetic models of absence epilepsy in the rat, 233 Dezsi, 2013, Ethosuximide reduces epileptogenesis and behavioral comorbidity in the GAERS model of genetic generalized epilepsy, Epilepsia, 54, 635, 10.1111/epi.12118 Du, 2015, Using patient-derived induced pluripotent stem cells to model and treat epilepsies, Curr. Neurol. Neurosci. Rep., 15, 588, 10.1007/s11910-015-0588-3 Dudek, 2010, Counterpoint to what is an epileptic seizure? by D’Ambrosio and Miller, Epilepsy Curr., 10, 91, 10.1111/j.1535-7511.2010.01368.x Duncan, 1991, Epilepsy and the blood-brain barrier, Br. J. Hosp. Med., 45, 32 Durham, 2015, Target engagement in lead generation, Bioorg. Med. Chem. Lett., 25, 998, 10.1016/j.bmcl.2014.12.076 Eastman, 2010, ECoG studies of valproate, carbamazepine and halothane in frontal-lobe epilepsy induced by head injury in the rat, Exp. Neurol., 224, 369, 10.1016/j.expneurol.2010.04.013 Eastman, 2011, Antiepileptic and antiepileptogenic performance of carisbamate after head injury in the rat: blind and randomized studies, J. Pharmacol. Exp. Ther., 336, 779, 10.1124/jpet.110.175133 Eastman, 2015, Optimized methods for epilepsy therapy development using an etiologically realistic model of focal epilepsy in the rat, Exp. Neurol., 264, 150, 10.1016/j.expneurol.2014.12.010 Engel, 2014, Epilepsy. foreword, Adv. Exp. Med. Biol., 813, v Engel, 2013, Epilepsy biomarkers, Epilepsia, 54, 61, 10.1111/epi.12299 Ess, 2013, Patient heal thyself: modeling and treating neurological disorders using patient-derived stem cells, Exp. Biol. Med. (Maywood), 238, 308, 10.1177/1535370213480713 Everett, 1944, Comparative anticonvulsive action of 3,5,5-trimethyloxazolidine-2,4-dione (Tridione), dilantin and phenobarbital, J. Pharmacol. Exp. Ther., 81, 402 Feldmann, 2013, P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study, Lancet Neurol., 12, 777, 10.1016/S1474-4422(13)70109-1 Fisher, 2005, Epileptic seizures and epilepsy: definitions proposed by the international league against epilepsy (ILAE) and the international bureau for epilepsy (IBE), Epilepsia, 46, 470, 10.1111/j.0013-9580.2005.66104.x Fisher, 2009, Update of the stroke therapy academic industry roundtable preclinical recommendations, Stroke, 40, 2244, 10.1161/STROKEAHA.108.541128 Florek-Luszczki, 2015, Effects of WIN 55,212-2 (a synthetic cannabinoid CB1 and CB2 receptor agonist) on the anticonvulsant activity of various novel antiepileptic drugs against 6 Hz-induced psychomotor seizures in mice, Pharmacol. Biochem. Behav., 130, 53, 10.1016/j.pbb.2015.01.003 Forcelli, 2013, Delayed effect of craniotomy on experimental seizures in rats, PLoS One, 8, e81401, 10.1371/journal.pone.0081401 French, 2009, Rational polytherapy, Epilepsia, 50, 63, 10.1111/j.1528-1167.2009.02238.x Friedman, 2012, Clinical trials for therapeutic assessment of antiepileptic drugs in the 21st century: obstacles and solutions, Lancet Neurol., 11, 827, 10.1016/S1474-4422(12)70177-1 Friedman, 2009, Blood-brain barrier breakdown-inducing astrocytic transformation: novel targets for the prevention of epilepsy, Epilepsy Res., 85, 142, 10.1016/j.eplepsyres.2009.03.005 Galanopoulou, 2015, Pathogenesis and new candidate treatments for infantile spasms and early life epileptic encephalopathies: a view from preclinical studies, Neurobiol. Dis., 79, 135, 10.1016/j.nbd.2015.04.015 Galanopoulou, 2012, Epilepsia, 53, 571, 10.1111/j.1528-1167.2011.03391.x Galanopoulou, 2013, Joint AES/ILAE translational workshop to optimize preclinical epilepsy research, Epilepsia, 54, 1, 10.1111/epi.12293 Gastens, 2008, Predictors of pharmacoresistant epilepsy: pharmacoresistant rats differ from pharmacoresponsive rats in behavioral and cognitive abnormalities associated with experimentally induced epilepsy, Epilepsia, 49, 1759, 10.1111/j.1528-1167.2008.01659.x Gidal, 2015, Seeking the Rational (or at least avoiding the irrational), Epilepsy Curr., 15, 260, 10.5698/1535-7511-15.5.260 Goddard, 1969, A permanent change in brain function resulting from daily electrical stimulation, Exp. Neurol., 25, 295, 10.1016/0014-4886(69)90128-9 Gorter, 2015, Which insights have we gained from the kindling and post-status epilepticus models?, J. Neurosci. Methods Guerrini, 2014, Genetic epilepsy syndromes without structural brain abnormalities: clinical features and experimental models, Neurotherapeutics, 11, 269, 10.1007/s13311-014-0267-0 Guillemain, 2012, Animal models to study aetiopathology of epilepsy: what are the features to model?, Epileptic. Disord., 14, 217, 10.1684/epd.2012.0528 Hanada, 2011, Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy, Epilepsia, 52, 1331, 10.1111/j.1528-1167.2011.03109.x Hardy, 2012, Double-masked, placebo-controlled study of intravenous levetiracetam for the treatment of status epilepticus and acute repetitive seizures in dogs, J. Vet. Intern. Med., 26, 334, 10.1111/j.1939-1676.2011.00868.x Harward, 2014, Aligning animal models with clinical epilepsy: where to begin?, Adv. Exp. Med. Biol., 813, 243, 10.1007/978-94-017-8914-1_19 Hay, 2014, Clinical development success rates for investigational drugs, Nat. Biotechnol., 32, 40, 10.1038/nbt.2786 Heinemann, 2012, Blood-brain barrier dysfunction, TGFbeta signaling, and astrocyte dysfunction in epilepsy, Glia, 60, 1251, 10.1002/glia.22311 Hirshler, 2010, Intracranial electrode implantation produces regional neuroinflammation and memory deficits in rats, Exp. Neurol., 222, 42, 10.1016/j.expneurol.2009.12.006 Honndorf, 2011, Female Wistar rats obtained from different breeders vary in anxiety-like behavior and epileptogenesis, Epilepsy Res., 94, 26, 10.1016/j.eplepsyres.2010.12.012 Hsieh, 2012, A new measure of cortical inhibition by mechanomyography and paired-pulse transcranial magnetic stimulation in unanesthetized rats, J. Neurophysiol., 107, 966, 10.1152/jn.00690.2011 Ioannidis, 2005, Why most published research findings are false, PLoS Med., 2, e124, 10.1371/journal.pmed.0020124 Jiang, 2007, Preliminary explorations of the role of mitochondrial proteins in refractory epilepsy: some findings from comparative proteomics, J. Neurosci. Res., 85, 3160, 10.1002/jnr.21384 Jonker, 2007, Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments?, Epilepsia, 48, 412, 10.1111/j.1528-1167.2006.00952.x Kandratavicius, 2014, Animal models of epilepsy: use and limitations, Neuropsychiatr. Dis. Treat., 10, 1693, 10.2147/NDT.S50371 Kaplan, 1985, The epileptic nature of rodent electrocortical polyspiking is still unproven, Exp. Neurol., 88, 425, 10.1016/0014-4886(85)90204-3 Kelly, 2015, Posttraumatic seizures and epilepsy in adult rats after controlled cortical impact, Epilepsy Res., 117, 104, 10.1016/j.eplepsyres.2015.09.009 Kelly, 2004, Spike-wave discharges: absence or not, a common finding in common laboratory rats, Epilepsy Curr., 4, 176, 10.1111/j.1535-7597.2004.04503.x Kharatishvili, 2010, Posttraumatic epilepsy, Curr. Opin. Neurol., 23, 183, 10.1097/WCO.0b013e32833749e4 Kilkenny, 2010, Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research, PLoS Biol., 8, e1000412, 10.1371/journal.pbio.1000412 Kimiskidis, 2014, Transcranial magnetic stimulation for the diagnosis and treatment of epilepsy, Curr. Opin. Neurol., 27, 236, 10.1097/WCO.0000000000000071 Kimmelman, 2011, Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty, PLoS Med., 8, e1001010, 10.1371/journal.pmed.1001010 Klein, 2015, Inter-individual variation in the effect of antiepileptic drugs in the intrahippocampal kainate model of mesial temporal lobe epilepsy in mice, Neuropharmacology, 90, 53, 10.1016/j.neuropharm.2014.11.008 Klitgaard, 2007, Levetiracetam: the first SV2A ligand for the treatment of epilepsy, Expert Opin. Drug Discov., 2, 1537, 10.1517/17460441.2.11.1537 Klitgaard, 2002, Use of epileptic animals for adverse effect testing, Epilepsy Res., 50, 55, 10.1016/S0920-1211(02)00068-2 Kola, 2004, Can the pharmaceutical industry reduce attrition rates?, Nat. Rev. Drug Discov., 3, 711, 10.1038/nrd1470 Koyama, 2012, GABAergic excitation after febrile seizures induces ectopic granule cells and adult epilepsy, Nat. Med., 18, 1271, 10.1038/nm.2850 Krall, 1978, Antiepileptic drug development: I. History and a program for progress, Epilepsia, 19, 393, 10.1111/j.1528-1157.1978.tb04506.x Krall, 1978, Antiepileptic drug development: II. Anticonvulsant drug screening, Epilepsia, 19, 409, 10.1111/j.1528-1157.1978.tb04507.x Kroll, 1998, Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means, Neurosurgery, 42, 1083, 10.1097/00006123-199805000-00082 Krupp, 2000, Tolerance to the anticonvulsant effects of lamotrigine on amygdala kindled seizures: cross-tolerance to carbamazepine but not valproate or diazepam, Exp. Neurol., 162, 278, 10.1006/exnr.1999.7343 Kwan, 2010, Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies, Epilepsia, 51, 1069, 10.1111/j.1528-1167.2009.02397.x Kwan, 2011, Drug-resistant epilepsy, N. Engl. J. Med., 365, 919, 10.1056/NEJMra1004418 Löscher, 2010, Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research, Pharmacol. Rev., 62, 668, 10.1124/pr.110.003046 Löscher, 2010, High seizure frequency prior to antiepileptic treatment is a predictor of pharmacoresistant epilepsy in a rat model of temporal lobe epilepsy, Epilepsia, 51, 89, 10.1111/j.1528-1167.2009.02183.x Löscher, 1991, Responses to NMDA receptor antagonists altered by epileptogenesis, Trends Pharmacol. Sci., 12, 52, 10.1016/0165-6147(91)90496-F Löscher, 1993, Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats, Eur. J. Pharmacol., 232, 147, 10.1016/0014-2999(93)90768-D Löscher, 1991, Kindling as a model of drug-resistant partial epilepsy: selection of phenytoin-resistant and nonresistant rats, J. Pharmacol. Exp. Ther., 258, 483 Löscher, 1988, Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations, Epilepsy Res., 2, 145, 10.1016/0920-1211(88)90054-X Löscher, 1994, Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation?, Epilepsy Res., 17, 95, 10.1016/0920-1211(94)90012-4 Löscher, 2006, Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs, Epilepsia, 47, 1253, 10.1111/j.1528-1167.2006.00607.x Löscher, 2011, Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma, Epilepsia, 52, 657, 10.1111/j.1528-1167.2011.03024.x Löscher, 1985, Evaluation of epileptic dogs as an animal model of human epilepsy, Arzneim–Forsch (Drug Res.), 35, 82 Löscher, 1986, Is amygdala kindling in rats a model for drug-resistant partial epilepsy?, Exp. Neurol., 93, 211, 10.1016/0014-4886(86)90160-3 Löscher, 1991, The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs: III. Pentylenetetrazol seizure models, Epilepsy Res., 8, 171, 10.1016/0920-1211(91)90062-K Löscher, 1991, The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs: II. Maximal electroshock seizure models, Epilepsy Res., 8, 79, 10.1016/0920-1211(91)90075-Q Löscher, 1993, Pharmacological characterization of phenytoin-resistant amygdala-kindled rats, a new model of drug-resistant partial epilepsy, Epilepsy Res., 15, 207, 10.1016/0920-1211(93)90058-F Löscher, 1995, Does prolonged implantation of depth electrodes predispose the brain to kindling?, Brain Res., 697, 197, 10.1016/0006-8993(95)00843-F Löscher, 1999, Effect of depth electrode implantation with or without subsequent kindling on GABA turnover in various rat brain regions, Epilepsy Res., 37, 95, 10.1016/S0920-1211(99)00038-8 Löscher, 2006, mGlu1 and mGlu5 receptor antagonists lack anticonvulsant efficacy in rodent models of difficult-to-treat partial epilepsy, Neuropharmacology, 50, 1006, 10.1016/j.neuropharm.2006.02.001 Löscher, 2013, New avenues for antiepileptic drug discovery and development, Nat. Rev. Drug Discov., 12, 757, 10.1038/nrd4126 Löscher, 2015, The enigma of the latent period in the development of symptomatic acquired epilepsy – Traditional view versus new concepts, Epilepsy Behav., 52, 78, 10.1016/j.yebeh.2015.08.037 Löscher, 1980, A comparative study of the pharmacology of inhibitors of GABA-metabolism, Naunyn-Schmiedeberg's Arch Pharmacol., 315, 119, 10.1007/BF00499254 Löscher, 1986, Experimental models for intractable epilepsy in nonprimate animal species, 25 Löscher, 1997, Animal models of intractable epilepsy, Prog. Neurobiol., 53, 239, 10.1016/S0301-0082(97)00035-X Löscher, 1999, Animal models of epilepsy and epileptic seizures, 19, 10.1007/978-3-642-60072-2_2 Löscher, 2002, Animal models of drug-resistant epilepsy, Novartis Found. Symp., 243, 149, 10.1002/0470846356.ch11 Löscher, 2005, Mechanisms of drug resistance, Epileptic. Disord., 7, 3 Löscher, 2006, Animal models of drug-refractory epilepsy, 551 Löscher, 2007, The pharmacokinetics of antiepileptic drugs in rats: consequences for maintaining effective drug levels during prolonged drug administration in rat models of epilepsy, Epilepsia, 48, 1245, 10.1111/j.1528-1167.2007.01093.x Löscher, 2009, Preclinical assessment of proconvulsant drug activity and its relevance for predicting adverse events in humans, Eur. J. Pharmacol., 610, 1, 10.1016/j.ejphar.2009.03.025 Löscher, 2011, Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs, Seizure, 20, 359, 10.1016/j.seizure.2011.01.003 Löscher, 2015, Single versus combinatorial therapies in status epilepticus: novel data from preclinical models, Epilepsy Behav., 49, 20, 10.1016/j.yebeh.2015.02.027 Löscher, 2016, Animal models of drug-refractory epilepsy Landis, 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature, 490, 187, 10.1038/nature11556 Langer, 2011, Marked strain and substrain differences in induction of status epilepticus and subsequent development of neurodegeneration, epilepsy, and behavioral alterations in rats, Epilepsy Res., 96, 207, 10.1016/j.eplepsyres.2011.06.005 Leclercq, 2015, Genetic background of mice strongly influences treatment resistance in the 6Hz seizure model, Epilepsia, 56, 310, 10.1111/epi.12893 Leclercq, 2015, Status epilepticus induction has prolonged effects on the efficacy of antiepileptic drugs in the 6-Hz seizure model, Epilepsy Behav., 49, 55, 10.1016/j.yebeh.2015.06.011 Leclercq, 2014, Low potency and limited efficacy of antiepileptic drugs in the mouse 6Hz corneal kindling model, Epilepsy Res., 108, 675, 10.1016/j.eplepsyres.2014.02.013 Leclercq, 2015, Cross-species pharmacological characterization of the allylglycine seizure model in mice and larval zebrafish, Epilepsy Behav., 45, 53, 10.1016/j.yebeh.2015.03.019 Leppik, 2011, Canine status epilepticus: a translational platform for human therapeutic trials, Epilepsia, 52, 31, 10.1111/j.1528-1167.2011.03231.x Leppik, 1996 Letts, 2014, Hidden in plain sight: spike-wave discharges in mouse inbred strains, Genes Brain Behav., 13, 519, 10.1111/gbb.12142 Libbey, 2011, Neurotropic viral infections leading to epilepsy: focus on Theiler's murine encephalomyelitis virus, Future Virol., 6, 1339, 10.2217/fvl.11.107 Lippman-Bell, 2013, AMPA receptor antagonist NBQX attenuates later-life epileptic seizures and autistic-like social deficits following neonatal seizures, Epilepsia, 54, 1922, 10.1111/epi.12378 Liu, 2013, Transient inhibition of TrkB kinase after status epilepticus prevents development of temporal lobe epilepsy, Neuron, 79, 31, 10.1016/j.neuron.2013.04.027 Luna-Munguia, 2011, Effects of high frequency electrical stimulation and R-verapamil on seizure susceptibility and glutamate and GABA release in a model of phenytoin-resistant seizures, Neuropharmacology, 61, 807, 10.1016/j.neuropharm.2011.05.027 Luszczki, 2012, Interactions of pregabalin with gabapentin, levetiracetam, tiagabine and vigabatrin in the mouse maximal electroshock-induced seizure model: a type II isobolographic analysis, Epilepsy Res., 98, 148, 10.1016/j.eplepsyres.2011.09.002 Müller, 2009, Differences in sensitivity to the convulsant pilocarpine in substrains and sublines of C57BL/6 mice, Genes Brain Behav., 8, 481, 10.1111/j.1601-183X.2009.00490.x Ma, 2013, P-glycoprotein alters blood-brain barrier penetration of antiepileptic drugs in rats with medically intractable epilepsy, Drug Des. Dev. Ther., 7, 1447 Marchi, 2009, Blood-brain barrier damage and brain penetration of antiepileptic drugs: role of serum proteins and brain edema, Epilepsia, 50, 664, 10.1111/j.1528-1167.2008.01989.x Matagne, 1998, Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man, Epilepsy Res., 31, 59, 10.1016/S0920-1211(98)00016-3 Matsumura, 2014, Isobolographic analysis of the mechanisms of action of anticonvulsants from a combination effect, Eur. J. Pharmacol., 741, 237, 10.1016/j.ejphar.2014.08.001 Mattson, 1992, A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic- clonic seizures in adults: the Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group, N. Engl. J. Med., 327, 765, 10.1056/NEJM199209103271104 McConnell, 2009, Implanted neural electrodes cause chronic, local inflammation that is correlated with local neurodegeneration, J. Neural Eng., 6, 056003, 10.1088/1741-2560/6/5/056003 Meldrum, 2002, Do preclinical seizure models preselect certain adverse effects of antiepileptic drugs, Epilepsy Res., 50, 33, 10.1016/S0920-1211(02)00066-9 Meunier, 1963, Propriétés pharmacodynamiques de l'acide n-dipropylacétique. 1er Mémoire: propriétés antiépileptiques, Thérapie, 18, 435 Mullard, 2011, Reliability of ‘new drug target' claims called into question, Nat. Rev. Drug Discov., 10, 643, 10.1038/nrd3545 Munana, 2010, Placebo effect in canine epilepsy trials, J. Vet. Intern. Med., 24, 166, 10.1111/j.1939-1676.2009.0407.x Munana, 2012, Evaluation of levetiracetam as adjunctive treatment for refractory canine epilepsy: a randomized, placebo-controlled, crossover trial, J. Vet. Intern. Med., 26, 341, 10.1111/j.1939-1676.2011.00866.x Muruganandan, 2008, Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism, Clin. Pharmacol. Ther., 83, 818, 10.1038/clpt.2008.50 Niespodziany, 1999, Chronic electrode implantation entails epileptiform field potentials in rat hippocampal slices, similarly to amygdala kindling, Epilepsy Res., 36, 69, 10.1016/S0920-1211(99)00027-3 Nitsch, 1986, Pathophysiological aspects of blood-brain barrier permeability in epileptic seizures, Adv. Exp. Med. Biol., 203, 175, 10.1007/978-1-4684-7971-3_13 O’Brien, 2013, Proposal for a ‘phase II’ multicenter trial model for preclinical new antiepilepsy therapy development, Epilepsia, 54, 70, 10.1111/epi.12300 Oby, 2006, The blood-brain barrier and epilepsy, Epilepsia, 47, 1761, 10.1111/j.1528-1167.2006.00817.x Parent, 2015, Reprogramming patient-derived cells to study the epilepsies, Nat. Neurosci., 18, 360, 10.1038/nn.3944 Patsalos, 2008, Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies, Epilepsia, 49, 1239, 10.1111/j.1528-1167.2008.01561.x Perrin, 2014, Preclinical research: make mouse studies work, Nature, 507, 423, 10.1038/507423a Perucca, 2005, Adverse effects of antiepileptic drugs, Acta Neurol. Scand. Suppl., 181, 30, 10.1111/j.1600-0404.2005.00506.x Perucca, 2014, Does gender influence susceptibility and consequences of acquired epilepsies?, Neurobiol. Dis., 72, 125, 10.1016/j.nbd.2014.05.016 Peterson, 1998, Electroshock, 1 Petito, 1977, Ultrastructural characteristics of the brain and blood-brain barrier in experimental seizures, Brain Res., 127, 251, 10.1016/0006-8993(77)90539-X Philip, 2009, Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials, Stroke, 40, 577, 10.1161/STROKEAHA.108.524330 Pitkänen, 2013, Issues related to development of antiepileptogenic therapies, Epilepsia, 54, 35, 10.1111/epi.12297 Polikov, 2005, Response of brain tissue to chronically implanted neural electrodes, J. Neurosci. Methods, 148, 1, 10.1016/j.jneumeth.2005.08.015 Postma, 2000, Lamotrigine treatment during amygdala-kindled seizure development fails to inhibit seizures and diminishes subsequent anticonvulsant efficacy, Epilepsia, 41, 1514, 10.1111/j.1499-1654.2000.001514.x Potschka, 1999, Corneal kindling in mice: a valid model for anticonvulsant drug screening?, 750 Potschka, 2002, A comparison of extracellular levels of phenytoin in amygdala and hippocampus of kindled and non-kindled rats, Neuroreport, 13, 167, 10.1097/00001756-200201210-00038 Potschka, 2004, Pharmacoresistance and expression of multidrug transporter P-glycoprotein in kindled rats, Neuroreport, 19, 1657, 10.1097/01.wnr.0000134840.10390.a4 Potschka, 2011, Impact of seizure activity on free extracellular phenytoin concentrations in amygdala-kindled rats, Neuropharmacology, 61, 909, 10.1016/j.neuropharm.2011.06.018 Potschka, 2013, Canine epilepsy as a translational model?, Epilepsia, 54, 571, 10.1111/epi.12138 Prinz, 2011, Believe it or not: how much can we rely on published data on potential drug targets?, Nat. Rev. Drug Discov., 10, 712, 10.1038/nrd3439-c1 Privitera, 2003, Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy, Acta Neurol. Scand., 107, 165, 10.1034/j.1600-0404.2003.00093.x Putnam, 1937, Experimental determination of the anticonvulsant properties of some phenyl derivatives, Science, 85, 525, 10.1126/science.85.2213.525 Racine, 1972, Modification of seizure activity by electrical stimulation: II. Motor seizure, Electroenceph. Clin. Neurophysiol., 32, 281, 10.1016/0013-4694(72)90177-0 Rakhade, 2011, Development of later life spontaneous seizures in a rodent model of hypoxia-induced neonatal seizures, Epilepsia, 52, 753, 10.1111/j.1528-1167.2011.02992.x Riban, 2002, Evolution of hippocampal epileptic activity during the development of hippocampal sclerosis in a mouse model of temporal lobe epilepsy, Neuroscience, 112, 101, 10.1016/S0306-4522(02)00064-7 Rodgers, 2015, Progressive, seizure-like, spike-wave discharges are common in both injured and uninjured sprague-Dawley rats: implications for the fluid percussion injury model of post-traumatic epilepsy, J. Neurosci., 35, 9194, 10.1523/JNEUROSCI.0919-15.2015 Rodgers, 2015 Rogawski, 2004, The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions, Nat. Med., 10, 685, 10.1038/nm1074 Rogawski, 2013, Neuroactive steroids for the treatment of status epilepticus, Epilepsia, 54, 93, 10.1111/epi.12289 Rogawski, 2013, The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs, Epilepsia, 54, 32 Rossetti, 2011, Management of refractory status epilepticus in adults: still more questions than answers, Lancet Neurol., 10, 922, 10.1016/S1474-4422(11)70187-9 Rowley, 2010, Comparative anticonvulsant efficacy in the corneal kindled mouse model of partial epilepsy: correlation with other seizure and epilepsy models, Epilepsy Res., 92, 163, 10.1016/j.eplepsyres.2010.09.002 Rundfeldt, 2014, The pharmacology of imepitoin: the first partial benzodiazepine receptor agonist developed for the treatment of epilepsy, Cns Drugs, 28, 29, 10.1007/s40263-013-0129-z Rundfeldt, 1990, Phenytoin potently increases the threshold for focal seizures in amygdala-kindled rats, Neuropharmacology, 29, 845, 10.1016/0028-3908(90)90159-O Rundfeldt, 2015, Efficacy, safety, and tolerability of imepitoin in dogs with newly diagnosed epilepsy in a randomized controlled clinical study with long-term follow up, BMC Vet. Res., 11, 228, 10.1186/s12917-015-0548-9 Russo, 2010, Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy, Epilepsia, 51, 1560, 10.1111/j.1528-1167.2009.02400.x Russo, 2011, Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model, Epilepsia, 52, 1341, 10.1111/j.1528-1167.2011.03112.x Sato, 1990, Kindling: basic mechanisms and clinical validity, Electroenceph. Clin. Neurophysiol., 76, 459, 10.1016/0013-4694(90)90099-6 Scantlebury, 2010, A model of symptomatic infantile spasms syndrome, Neurobiol. Dis., 37, 604, 10.1016/j.nbd.2009.11.011 Schauwecker, 2002, Complications associated with genetic background effects in models of experimental epilepsy, Prog. Brain Res., 135, 139, 10.1016/S0079-6123(02)35014-3 Schauwecker, 2011, The relevance of individual genetic background and its role in animal models of epilepsy, Epilepsy Res., 97, 1, 10.1016/j.eplepsyres.2011.09.005 Schmidt, 2005, Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms, Epilepsia, 46, 858, 10.1111/j.1528-1167.2005.54904.x Schmidt, 2009, Drug treatment of epilepsy: options and limitations, Epilepsy Behav., 15, 56, 10.1016/j.yebeh.2009.02.030 Schmutz, 1994, Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action, Epilepsia, 35, S47, 10.1111/j.1528-1157.1994.tb05967.x Schuck, 2015, Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape, AAPS J., 17, 462, 10.1208/s12248-014-9716-2 Simonato, 2012, Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design, Epilepsia, 53, 1860, 10.1111/j.1528-1167.2012.03541.x Simonato, 2013, Issues for new antiepilepsy drug development, Curr. Opin. Neurol., 26, 195, 10.1097/WCO.0b013e32835efe29 Simonato, 2014, The challenge and promise of anti-epileptic therapy development in animal models, Lancet Neurol., 13, 949, 10.1016/S1474-4422(14)70076-6 Smyth, 2002, Effects of antiepileptic drugs on induced epileptiform activity in a rat model of dysplasia, Epilepsy Res., 50, 251, 10.1016/S0920-1211(02)00051-7 Srivastava, 2013, Carbamazepine, but not valproate, displays pharmacoresistance in lamotrigine-resistant amygdala kindled rats, Epilepsy Res., 104, 26, 10.1016/j.eplepsyres.2012.10.003 Srivastava, 2013, Rapid loss of efficacy to the antiseizure drugs lamotrigine and carbamazepine: a novel experimental model of pharmacoresistant epilepsy, Epilepsia, 54, 1186, 10.1111/epi.12234 Stables, 2002, Models for epilepsy and epileptogenesis: report from the NIH workshop Bethesda, Maryland, Epilepsia, 43, 1410, 10.1046/j.1528-1157.2002.06702.x Stables, 2003, Therapy discovery for pharmacoresistant epilepsy and for disease-modifying therapeutics: summary of the NIH/NINDS/AES models II workshop, Epilepsia, 44, 1472, 10.1111/j.0013-9580.2003.32803.x Stafstrom, 2014, Epilepsy comorbidities: how can animal models help?, Adv. Exp. Med. Biol., 813, 273, 10.1007/978-94-017-8914-1_22 Swinyard, 1952, Comparative assay of antiepileptic drugs in mice and rats, J. Pharmacol. Exp. Ther., 106, 319 Swinyard, 1949, Laboratory assay of clinically effective antiepileptic drugs, J. Am. Pharm. Assoc., 38, 201, 10.1002/jps.3030380409 Töllner, 2011, The anticonvulsant response to valproate in kindled rats is correlated with its effect on neuronal firing in the substantia nigra pars reticulata: a new mechanism of pharmacoresistance, J. Neurosci., 31, 16423, 10.1523/JNEUROSCI.2506-11.2011 Takahashi, 2006, Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors, Cell, 126, 663, 10.1016/j.cell.2006.07.024 Taylor, 2002, Gabapentin, mechanisms of action, 321 Tipold, 2015, Clinical efficacy and safety of imepitoin in comparison with phenobarbital for the control of idiopathic epilepsy in dogs, J. Vet. Pharmacol. Ther., 38, 160, 10.1111/jvp.12151 Toman, 1946, Properties of maximal seizures and their alteration by anticonvulsant drugs and other agents, J. Neurophysiol., 9, 231, 10.1152/jn.1946.9.3.231 Toman, 1951, Experimental psychomotor seizures, Electroencephalogr. Clin. Neurophysiol., 3, 253 Treiman, 2002, Will brain damage after status epilepticus be history in 2010?, Prog. Brain Res., 135, 471, 10.1016/S0079-6123(02)35044-1 Vaitkevicius, 2013, Successful allopregnanolone treatment of new onset refractory statusepilepticus (NORSE) syndrome: first in man experience, Epilepsia, 54, 106 van Rijn, 1994, Effects of lamotrigine on absence seizures in rats, Pol. J. Pharmacol., 46, 467 van Vliet, 2007, Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy, Brain, 130, 521, 10.1093/brain/awl318 Vartanian, 2006, Activity profile of pregabalin in rodent models of epilepsy and ataxia, Epilepsy Res., 68, 189, 10.1016/j.eplepsyres.2005.11.001 Vela, 2014, Vol. 62 Vezzani, 2016, Infections, inflammation and epilepsy, Acta Neuropathol., 10.1007/s00401-015-1481-5 Volk, 2005, Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures, Brain, 128, 1358, 10.1093/brain/awh437 Volk, 2006, Antiepileptic drug resistant rats differ from drug responsive rats in hippocampal neurodegeneration and GABAA-receptor ligand-binding in a model of temporal lobe epilepsy, Neurobiol. Dis., 21, 633, 10.1016/j.nbd.2005.09.006 Walker, 2015, Seize the moment that is thine: how should we define seizures?, Brain, 138, 1127, 10.1093/brain/awv091 Wartha, 2014, Fit-for purpose use of mouse models to improve predictivity of cancer therapeutics evaluation, Pharmacol. Ther., 142, 351, 10.1016/j.pharmthera.2014.01.001 Wasterlain, 2008, Mechanistic and pharmacologic aspects of status epilepticus and its treatment with new antiepileptic drugs, Epilepsia, 49, 63, 10.1111/j.1528-1167.2008.01928.x Wasterlain, 2009, Molecular basis of self-sustaining seizures and pharmacoresistance during status epilepticus: the receptor trafficking hypothesis revisited, Epilepsia, 50, 16, 10.1111/j.1528-1167.2009.02375.x Wasterlain, 2013, Epileptogenesis in the developing brain, Handb. Clin. Neurol., 111, 427, 10.1016/B978-0-444-52891-9.00046-4 Wehling, 2011, Drug development in the light of translational science: shine or shade?, Drug Discov. Today, 16, 1076, 10.1016/j.drudis.2011.07.008 Weiss, 1991, Development and reversal of contingent inefficacy and tolerance to the anticonvulsant effects of carbamazepine, Epilepsia, 32, 140, 10.1111/j.1528-1157.1991.tb05626.x White, 2014, Searching for the ideal antiepileptogenic agent in experimental models: single treatment versus combinatorial treatment strategies, Neurotherapeutics, 11, 373, 10.1007/s13311-013-0250-1 White, 2002, Discovery and preclinical development of antiepileptic drugs, 36 White, 2006, Therapeutic assays for the identification and characterization of antiepileptic and antiepileptogenic drugs, 539 Wilcox, 2013, Issues related to development of new antiseizure treatments, Epilepsia, 54, 24, 10.1111/epi.12296 Williams, 2009, Development of spontaneous recurrent seizures after kainate-induced status epilepticus, J. Neurosci., 29, 2103, 10.1523/JNEUROSCI.0980-08.2009 Willner, 2015, Treatment-resistant depression: are animal models of depression fit for purpose?, Psychopharmacology (Berl.), 232, 3473, 10.1007/s00213-015-4034-7 Woodbury, 1983, Experimental models of status epilepticus and mechanisms of drug action, Vol. 34: Status Epilepticus, 149 Zeng, 2009, Enhanced synaptic vesicle traffic in hippocampus of phenytoin-resistant kindled rats, Neurochem. Res., 34, 899, 10.1007/s11064-008-9856-9